Session date: 
09/29/2017 - 12:15pm to 1:00pm

Gonda 8-104/Joseph 1-242

Multiple Sclerosis
Diana Londono, M.D.
"Ocrelizumab, The New Kid on the Block, The Good, the Bad, and More"

Learning objectives:
Describe the role of B cells in the pathogenesis of MS and the role of B-cell modulation in its treatment
Summarize the current clinical trial data for the B cell targeting therapy (Ocrelizumab) for management of relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis
Integrate the B-cell targeted therapy (Ocrelizumab) into the discussion of therapy selection for the management of primary progressive multiple sclerosis

The presenter (nor spouse/partner) does not have a relevant financial relationship to disclose and does not intend to discuss an off-label/investigative use of a commercial product/device.

Where did the idea for the course originate?: 
Minnesota
Please login or register to take this course.
Where did the idea for the course originate?: 
Minnesota